StockTipsArenaBeta

BUY Onesource Specialty Pharma Limited — IDBI Capital

BUYOnesource Specialty Pharma Limited
Onesource Specialty Pharma share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred 1–3 months)28 Jul 2026via IDBI Capital Research Calls Telegram

Entry₹1,728Stated
Target₹1,865
Total upside +7.93% (call closed)
Stop loss₹1,665-3.65% risk
Exit₹1,66530 Jul 2026, 12:07 pm
Stop-loss hit-3.65%
Follow IDBI Capital for new calls(32% target hit, 187 closed calls)Get alertsWatch ONESOURCE for new buy/sell callsGet alertsSee 42 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Jul 2026
2 supporting2 neutral0 opposing
Supports the BUY call (2)

1 advisor has an active long-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·26 Jul · 4d ago

OneSource Specialty Pharma Ltd reported strong Q1FY27 results with a 37% YoY increase in revenue and a 39% YoY increase in EBITDA.

BSE · Company Update·24 Jul · 5d ago

(opens in new tab)
Neutral / worth noting (2)

Onesource Specialty Pharma Limited announced its unaudited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors.

NSE · Outcome of Board Meeting·24 Jul · 5d ago

(opens in new tab)

Onesource Specialty Pharma Ltd announced the outcome of its Board meeting held on July 24, 2026. The board approved the unaudited financial results (Standalone and Consolidated) for the quarter ended

BSE · Board Meeting·24 Jul · 5d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Onesource Specialty Pharma

All analyst calls on Onesource Specialty Pharma

More from IDBI Capital

Every call and its outcome